Unknown

Dataset Information

0

11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.


ABSTRACT: 11C-methionine (MET) has recently emerged as an accurate marker of tumor burden and disease activity in patients with multiple myeloma (MM). This dual-center study aimed at further corroboration of the superiority of MET as positron emission tomography (PET) tracer for staging and re-staging MM, as compared to 18F-2`-deoxy-2`-fluoro-D-glucose (FDG). 78 patients with a history of solitary plasmacytoma (n=4), smoldering MM (SMM, n=5), and symptomatic MM (n=69) underwent both MET- and FDG-PET/computed tomography (CT) at the University Centers of Würzburg, Germany and Navarra, Spain. Scans were compared on a patient and on a lesion basis. Inter-reader agreement was also evaluated. In 2 patients, tumor biopsies for verification of discordant imaging results were available. MET-PET detected focal lesions (FL) in 59/78 subjects (75.6%), whereas FDG-PET/CT showed lesions in only 47 patients (60.3%; p<0.01), accordingly disease activity would have been missed in 12 patients. Directed biopsies of discordant results confirmed MET-PET/CT results in both cases. MET depicted more FL in 44 patients (56.4%; p<0.01), whereas in two patients (2/78), FDG proved superior. In the remainder (41.0%, 32/78), both tracers yielded comparable results. Inter-reader agreement for MET was higher than for FDG (? = 0.82 vs ? = 0.72). This study demonstrates higher sensitivity of MET in comparison to standard FDG to detect intra- and extramedullary MM including histologic evidence of FDG-negative, viable disease exclusively detectable by MET-PET/CT. MET holds the potential to replace FDG as functional imaging standard for staging and re-staging of MM.

PROVIDER: S-EPMC5562228 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4729773 | BioStudies
2020-01-01 | S-EPMC7226577 | BioStudies
1000-01-01 | S-EPMC3360901 | BioStudies
| S-EPMC7025551 | BioStudies
2018-01-01 | S-EPMC5773418 | BioStudies
1000-01-01 | S-EPMC4723987 | BioStudies
2020-01-01 | S-EPMC7344296 | BioStudies
2017-01-01 | S-EPMC5519227 | BioStudies
1000-01-01 | S-EPMC5409954 | BioStudies
2020-01-01 | S-EPMC7241233 | BioStudies